The revenue generated through AI-based solutions in the pharmaceutical industry is projected to rise at a CAGR of 21.94% and reach $2.199 billion by 2022.

According to Bender, regulating the use of AI in the pharmaceutical industry may be difficult. “Data, methods and use cases are very diverse and there is no one-size-fits-all approach,” he says.

The AI Revolution is Underway in the Pharmaceutical Industry The global pharmaceutical giant, AstraZeneca (NDQ: AZN), shows promise with their AI implementation strategy in drug development.

The U.S. Artificial intelligence (AI) in pharmaceutical market was estimated at USD 0.47 billion in 2024 and is expected to reach USD 3.67 billion by 2032, at a CAGR of 29.19% during the forecast ...

Conduit Pharmaceuticals and Sarborg Limited collaborate to integrate AI in drug development, enhancing efficiency and reducing costs.

The U.S. and European Union had first struck a trade agreement in July, but many details were left unresolved at the time.

Industry-leading pharmaceutical firms are adopting AI to drive value for the future of their enterprise. Several companies in the PPH ETF are currently integrating AI into their operations.

The European Union and the United States have published a joint statement, spelling out in writing the terms of the trade ...

Recently, pharmaceutical companies have been demonstrating a vivid interest in artificial intelligence (AI) applications for various research needs, catalyzed by the illustrative practical ...

This doesn’t mean that big pharma firms aren’t using AI; we’ve heard separately, for example, that Pfizer now has over 150 AI projects underway. But few of them are at the core of drug ...